login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EFFECTOR THERAPEUTICS INC (EFTR) Stock News
USA
- NASDAQ:EFTR -
US28202V2079
-
Common Stock
0.18
USD
-0.09 (-32.56%)
Last: 7/2/2024, 8:16:09 PM
0.155
USD
-0.02 (-13.89%)
After Hours:
7/2/2024, 8:16:09 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EFTR Latest News, Press Relases and Analysis
All
Press Releases
a year ago - By: InvestorPlace
- Mentions:
CSSE
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
a year ago - By: InvestorPlace
- Mentions:
OPTX
WENA
VLCN
RIVN
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
a year ago - By: Benzinga
- Mentions:
ALIM
AREB
AGFY
ALLR
...
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
a year ago - By: Benzinga
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
a year ago - By: BusinessInsider
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
a year ago - By: InvestorPlace
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
2 years ago - By: BusinessInsider
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
2 years ago - By: InvestorPlace
- Mentions:
STOK
CHEK
OPGN
CISS
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
2 years ago - By: InvestorPlace
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2 years ago - By: Seeking Alpha
Effector Therapeutics announces $15M registered direct offering (NASDAQ:EFTR)
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2 years ago - By: eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2 years ago - By: InvestorPlace
- Mentions:
CISS
CRGE
ONCO
AFIB
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Please enable JavaScript to continue using this application.